Lineage Cell Therapeutics' Q2 Loss Widens Amid R&D Spend

TL;DR

**LCTX's cash burn is accelerating, putting pressure on its promising but costly pipeline; expect continued volatility.**

AI Summary

Lineage Cell Therapeutics, Inc. reported total revenues of $1.5 million for the six months ended June 30, 2025, a decrease from $2.0 million in the prior year period, primarily due to a reduction in collaboration revenues. The company experienced a net loss of $17.6 million for the six months ended June 30, 2025, compared to a net loss of $16.2 million for the same period in 2024, representing an 8.6% increase in net loss. Research and development expenses increased to $12.5 million from $11.8 million, reflecting continued investment in their clinical programs. General and administrative expenses also rose to $7.1 million from $6.5 million. The company's strategic outlook focuses on advancing its cell therapy pipeline, including the OpRegen program for dry AMD and the VAC2 program for cancer, despite the increased operational costs. Cash and cash equivalents stood at $45.3 million as of June 30, 2025, down from $55.1 million at December 31, 2024, indicating a burn rate that warrants attention.

Why It Matters

Lineage Cell Therapeutics' widening net loss and declining revenue signal increased pressure on its cash reserves, which could impact its ability to fund critical clinical trials for its cell therapy pipeline, including OpRegen and VAC2. For investors, this raises questions about the long-term viability and potential for dilution if the company needs to raise additional capital. Employees and customers could face uncertainty if financial constraints slow down product development or market entry. In the competitive cell therapy landscape, a slower pace of innovation due to financial strain could allow rivals to gain a significant advantage, potentially impacting Lineage's market position and future growth prospects.

Risk Assessment

Risk Level: high — The company reported a net loss of $17.6 million for the six months ended June 30, 2025, an increase from $16.2 million in the prior year, indicating a growing burn rate. Cash and cash equivalents decreased from $55.1 million at December 31, 2024, to $45.3 million at June 30, 2025, representing a 17.8% decline in cash over six months, which suggests a limited runway without further financing.

Analyst Insight

Investors should closely monitor Lineage Cell Therapeutics' cash position and future financing plans. Consider reducing exposure or holding off on new investments until there's clearer evidence of successful clinical trial progression or a strategic partnership that alleviates financial pressure.

Financial Highlights

revenue

$1.5M

net Income

-$17.6M

cash Position

$45.3M

revenue Growth

-25.0%

Revenue Breakdown

Key Numbers

• $1.5M — Total Revenues (Decreased from $2.0M in prior year period for six months ended June 30, 2025.)
• -$17.6M — Net Loss (Increased from -$16.2M in prior year period for six months ended June 30, 2025.)
• $45.3M — Cash and Cash Equivalents (Decreased from $55.1M at December 31, 2024, indicating significant cash burn.)
• $12.5M — R&D Expenses (Increased from $11.8M in prior year period, reflecting continued investment.)
• 8.6% — Increase in Net Loss (Percentage increase in net loss from $16.2 million to $17.6 million year-over-year.)

Key Players & Entities

• Lineage Cell Therapeutics, Inc. (company) — filer of the 10-Q
• Broadwood Partners LP (company) — investor mentioned in the filing
• Roche (company) — partner in an agreement
• Israel Innovation Authority (regulator) — partner in an agreement
• Es Cell International Pte Ltd (company) — entity mentioned in the filing
• Hadasit (company) — partner in an agreement
• $1.5 million (dollar_amount) — total revenues for six months ended June 30, 2025
• $17.6 million (dollar_amount) — net loss for six months ended June 30, 2025
• $45.3 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $12.5 million (dollar_amount) — research and development expenses for six months ended June 30, 2025

FAQ

Risk Factors

• Increasing Net Loss and Cash Burn [high — financial]: The company reported a net loss of $17.6 million for the six months ended June 30, 2025, an increase of 8.6% from $16.2 million in the prior year period. Concurrently, cash and cash equivalents decreased to $45.3 million from $55.1 million at December 31, 2024, indicating a significant cash burn rate that requires careful management.
• Rising Research and Development Expenses [medium — operational]: Research and development expenses increased to $12.5 million for the six months ended June 30, 2025, up from $11.8 million in the same period last year. This rise reflects continued investment in clinical programs, such as OpRegen for dry AMD and VAC2 for cancer, which are crucial for future growth but contribute to higher operational costs.
• Increased General and Administrative Expenses [medium — operational]: General and administrative expenses also saw an increase, rising to $7.1 million for the six months ended June 30, 2025, from $6.5 million in the prior year period. This increase, while smaller in absolute terms than R&D, adds to the overall cost structure and impacts the net loss.
• Clinical Trial Success and Regulatory Approval [high — regulatory]: The company's success is heavily dependent on the successful development and regulatory approval of its cell therapy pipeline, including OpRegen and VAC2. Delays or failures in clinical trials or the regulatory approval process could significantly impact future revenues and the company's viability.
• Competition in the Cell Therapy Market [medium — market]: The cell therapy market is highly competitive, with numerous companies investing heavily in research and development. Lineage Cell Therapeutics faces competition from established pharmaceutical companies and emerging biotech firms, which could affect market share and pricing power.

Industry Context

Lineage Cell Therapeutics operates in the highly competitive and rapidly evolving cell therapy sector. This industry is characterized by significant investment in research and development, long product development cycles, and stringent regulatory oversight. Key trends include advancements in gene editing, personalized medicine, and the increasing focus on rare diseases and oncology.

Regulatory Implications

The company's progress is subject to rigorous regulatory review by bodies like the FDA. Delays in clinical trials, failure to meet efficacy endpoints, or manufacturing challenges can lead to significant setbacks and impact the timeline for potential market approval and revenue generation.

What Investors Should Do

1. Monitor cash burn rate closely.
2. Evaluate R&D pipeline progress and milestones.
3. Assess the sustainability of revenue streams.

Glossary

Collaboration Revenues

Revenue generated from agreements with other companies where Lineage Cell Therapeutics provides services, licenses technology, or shares in development costs and potential future profits. (This is the primary source of revenue for Lineage Cell Therapeutics in the reported period, and its decrease significantly impacted the overall revenue performance.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (Indicates the company's profitability. An increasing net loss, as seen here, suggests growing expenses or declining revenues, impacting financial health.)

Cash and Cash Equivalents

Highly liquid short-term investments that can be readily converted into cash, such as money market funds and treasury bills. (Represents the company's immediate liquidity. A decrease in this amount signifies cash being spent, highlighting the company's burn rate.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. For biotech companies, this includes clinical trials and lab work. (These expenses are critical for the future growth of a biotech company like Lineage Cell Therapeutics, but they also represent a significant cost driver.)

General and Administrative Expenses

Costs associated with the overall management and operation of a business, not directly tied to the production of goods or services. This includes salaries for executives, legal fees, and office expenses. (These expenses contribute to the company's overhead. An increase can put pressure on profitability.)

Year-Over-Year Comparison

Compared to the prior year period, Lineage Cell Therapeutics reported a 25% decrease in total revenues for the six months ended June 30, 2025, primarily driven by lower collaboration revenues. This revenue decline, coupled with increased operating expenses in both R&D ($12.5M vs $11.8M) and G&A ($7.1M vs $6.5M), has led to an 8.6% increase in the net loss to $17.6 million. The company's cash position has also declined, reflecting a higher burn rate.

Filing Documents

• lctx-20250630.htm (10-Q) — 2663KB
• lctx-ex31_1.htm (EX-31.1) — 16KB
• lctx-ex31_2.htm (EX-31.2) — 14KB
• lctx-ex32_1.htm (EX-32.1) — 13KB
• 0000950170-25-107333.txt ( ) — 11238KB
• lctx-20250630.xsd (EX-101.SCH) — 1740KB
• lctx-20250630_htm.xml (XML) — 2014KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Loss 7 Condensed Consolidated Statements of Changes in Shareholders' Equity 8 Condensed Consolidated Statements of Cash Flows 10 Notes to the Condensed Consolidated Interim Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Result of Operations

Management's Discussion and Analysis of Financial Condition and Result of Operations 30 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 38 Item 4.

Controls and Procedures

Controls and Procedures 38 PART II. OTHER INFORMATION 39 Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A.

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 39 Item 3. Defaults Upon Senior Securities 39 Item 4. Mine Safety Disclosures 39 Item 5. Other Information 39 Item 6. Exhibits 40

Signatures

Signatures 41 2 SPE CIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations" of this report, but are also contained elsewhere in this report. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical fact contained in this report are forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements in this report include, but are not limited to, statements about: the potential to receive developmental, regulatory, and commercialization milestone and royalty payments under our Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc.; our continued ability to successfully manufacture our product candidates in a reproducible, scalable, and cost-effective manner, for clinical development and, if approved, for commercialization, including our future capability of producing several million doses of OpRegen; our plans to leverage our expertise to produce a cost-effective, scalable, and consistent supply of allogeneic cell transplant product candidates for ourselves and others, including for indications

View Full Filing

View this 10-Q filing on SEC EDGAR